Marinus Pharmaceuticals (MRNS) - News Mentions

Sign up to add (MRNS) to your portfolio and access more historical data.

0 100%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 100%
Gilead Sciences
Gilead Sciences
GILD		 0 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 100%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com
November 21
What is HC Wainwright’s Estimate for MRNS FY2024 Earnings?
November 18
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Brokerages
November 18
Marinus Pharmaceuticals Board Members Resign, Prompting Director ReductionOn November 14, 2024, Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) experienced a significant change within its Board of Directors. Charles Austin, Saraswathy V. Nochur, Ph.D.,
November 16
Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Neutral” Rating from HC Wainwright
November 16
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
November 14
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
November 12
Marinus Pharmaceuticals: Q3 Earnings Snapshot
November 12
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)
November 12
Marinus Pharmaceuticals’ (MRNS) Hold Rating Reaffirmed at TD Cowen
October 29
Marinus Pharmaceuticals (NASDAQ:MRNS) Given Neutral Rating at HC Wainwright
October 29
Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by JMP Securities
October 26
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by Jefferies Financial Group
October 25
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Moderate Buy” by Analysts
October 25
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital
October 24

How often is Marinus Pharmaceuticals mentioned in the news?

Marinus Pharmaceuticals was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Marinus Pharmaceuticals performing compared to its industry peers?

Marinus Pharmaceuticals underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Marinus Pharmaceuticals in the last month?

There has been no significant change in the number of news mentions for Marinus Pharmaceuticals' compared to the last month.

Why is it important to track news mentions for Marinus Pharmaceuticals?

By monitoring mentions in the news for Marinus Pharmaceuticals, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Marinus Pharmaceuticals, ultimately improving their investment strategies.

Sign up and get more insights on Marinus Pharmaceuticals.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact